Century Therapeutics Regains Nasdaq Compliance, Halts Reverse Split

Century Therapeutics ( (IPSC) ) just unveiled an update.

On January 22, 2026, Century Therapeutics, Inc. held a virtual special meeting of stockholders at which shareholders approved an amendment to the company’s certificate of incorporation authorizing a potential reverse stock split of its common shares at a ratio between 1-for-5 and 1-for-30, subject to the board’s discretion. On the same day, the company received notice from Nasdaq that it had regained compliance with the exchange’s minimum $1.00 bid price requirement and all other continued listing standards, leading Century Therapeutics to announce it does not intend to implement the reverse stock split, a decision that stabilizes its listing status and avoids the immediate dilutionary and structural impacts such a split might have had on existing shareholders.

The most recent analyst rating on (IPSC) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.

Spark’s Take on IPSC Stock

According to Spark, TipRanks’ AI Analyst, IPSC is a Neutral.

The score is mainly constrained by weak financial performance driven by persistent, deep negative operating and free cash flow and ongoing losses. Technicals are supportive with strong momentum versus moving averages, but very overbought RSI/Stoch readings temper the outlook. Corporate events add a positive offset via strengthened financing and pipeline progress, while valuation remains challenging due to negative earnings and no dividend support.

To see Spark’s full report on IPSC stock, click here.

More about Century Therapeutics

Century Therapeutics, Inc. is a biotechnology company focused on developing innovative cell-based therapies, operating within the life sciences sector and targeting disease areas where advanced therapeutic platforms can address significant unmet medical needs.

Average Trading Volume: 1,851,012

Technical Sentiment Signal: Buy

Current Market Cap: $167.8M

See more insights into IPSC stock on TipRanks’ Stock Analysis page.